Efficacy and safety of tarenflurbil, a selective a beta 42-lowering agent, in Alzheimer's disease (AD): A phase 2 trial of up to 24 months of treatment
主要な著者: | Black, S, Wilcock, G, Zavitz, K, Hendrix, S, Swabb, E |
---|---|
フォーマット: | Conference item |
出版事項: |
2008
|
類似資料
-
Efficacy and safety of tarenflurbil (flurizan), a selective Abeta42-lowering agent, in Alzheimer's disease (AD): A phase 2 trial of up to 24 months of treatment
著者:: Wilcock, G, 等
出版事項: (2007) -
Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
著者:: Wilcock, G, 等
出版事項: (2008) -
Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.
著者:: Green, R, 等
出版事項: (2009) -
Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective ab42-lowering agent, in mild Alzheimer's disease (AD): Results of a 12-month Phase 2 trial and 1-year follow-on study
著者:: Black, S, 等
出版事項: (2006) -
Flurizan, (MPC-7869, (R)-flurbiprofen) a selective A beta-42 lowering agent in patients with mild to moderate Alzheimer's disease: A randomised, placebo-controlled, double blind trial
著者:: Wilcock, G, 等
出版事項: (2005)